Nanoparticle-based pazopanib shows promise in OA

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-03-19 DOI:10.1038/s41584-024-01104-w

Rebecca Kelsey

引用次数: 0

Abstract

A nanoparticle-based formulation of the anticancer drug pazopanib, which inhibits VEGFR1 and VEGFR2, shows promise as a disease-modifying drug for osteoarthritis.

查看原文本刊更多论文

基于纳米颗粒的帕唑帕尼有望治疗骨关节炎

一种抑制血管内皮生长因子受体1和血管内皮生长因子受体2的抗癌药物帕唑帕尼纳米颗粒制剂有望成为骨关节炎的疾病改变药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.